Bradykinin Antagonists as Anti-Cancer Agents

Author(s): J. M. Stewart

Journal Name: Current Pharmaceutical Design

Volume 9 , Issue 25 , 2003

Become EABM
Become Reviewer
Call for Editor


The nonapeptide bradykinin is an important growth factor for many cancers. Certain peptide and non-peptide bradykinin antagonists show remarkable anti-cancer activities in both in vitro and in vivo cancer models, especially of lung and prostate cancers. Bradykinin antagonists stimulate apoptosis in cancers by a novel “biased agonist” mechanism: they block intracellular increase of calcium concentration but stimulate the MAP kinase pathway. This unbalanced effect stimulates caspase activation. In nude mouse xenotransplants of lung and prostate cancers the antagonists inhibit angiogenesis and activation of membrane metalloproteases (MMP 2 and 9). In the xenotransplants certain bradykinin antagonists showed higher potency than standard anti-cancer drugs, without evident toxicity to the hosts. These compounds offer great promise for development of new anti-cancer drugs.

Keywords: Bradykinin, peptide, xenotransplants, antagonists, metalloproteases

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2003
Page: [2036 - 2042]
Pages: 7
DOI: 10.2174/1381612033454171
Price: $65

Article Metrics

PDF: 13